Tango Therapeutics reports an 82% response rate in pancreatic cancer trial
Early targeted data shows shrinking tumors in advanced disease, demonstrating how computational genetic profiling can pinpoint vulnerable cellular pathways when conventional chemotherapy fails.
Pancreatic ductal adenocarcinoma remains one of the least forgiving diagnoses in medicine, carrying a five-year survival rate near 13%. Early clinical trial data from Tango Therapeutics offers a rare signal: an 82% disease control and response rate in an early-phase cohort testing a combination regimen of their PRMT5 inhibitor (TNG462) paired with a KRAS G12D inhibitor for patients with MTAP-deleted advanced solid tumors.
The mechanism relies on synthetic lethality. When tumors lose the MTAP gene—a deletion present in roughly 30% of pancreatic cancers—they become selectively dependent on the PRMT5 enzyme to survive. Computational chemistry platforms designed this specific molecule to spare healthy red blood cells while disabling the cancer cells. This target was historically considered undruggable because previous compounds caused toxic, treatment-limiting anemia.
An 82% response rate in a small phase 1/2 cohort must be evaluated cautiously. Early oncology trials select for patients resilient enough to meet strict enrollment criteria, and acquired resistance often emerges within nine to twelve months as malignant cells mutate. The meaningful metric will be progression-free survival across larger multi-center cohorts over the next two years.
If you or a family member face a pancreatic cancer diagnosis, request comprehensive genomic profiling of the biopsy tissue immediately. Knowing whether a tumor carries an MTAP deletion or a KRAS mutation determines whether clinical trial registries hold genuine therapeutic options beyond standard gemcitabine combinations.
The longer view
One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.